Literature DB >> 24899306

Sphingolipid lysosomal storage disorders.

Frances M Platt1.   

Abstract

Lysosomal storage diseases are inborn errors of metabolism, the hallmark of which is the accumulation, or storage, of macromolecules in the late endocytic system. They are monogenic disorders that occur at a collective frequency of 1 in 5,000 live births and are caused by inherited defects in genes that mainly encode lysosomal proteins, most commonly lysosomal enzymes. A subgroup of these diseases involves the lysosomal storage of glycosphingolipids. Through our understanding of the genetics, biochemistry and, more recently, cellular aspects of sphingolipid storage disorders, we have gained insights into fundamental aspects of cell biology that would otherwise have remained opaque. In addition, study of these disorders has led to significant progress in the development of therapies, several of which are now in routine clinical use. Emerging mechanistic links with more common diseases suggest we need to rethink our current concept of disease boundaries.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24899306     DOI: 10.1038/nature13476

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  112 in total

1.  Lessons learnt from animal models: pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Kim M Hemsley; John J Hopwood
Journal:  J Inherit Metab Dis       Date:  2010-05-07       Impact factor: 4.982

Review 2.  Gaucher's disease: clinical features and natural history.

Authors:  T M Cox; J P Schofield
Journal:  Baillieres Clin Haematol       Date:  1997-12

3.  NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.

Authors:  Mylvaganam Jeyakumar; David A Smith; Ian M Williams; Mario Cortina Borja; David C A Neville; Terry D Butters; Raymond A Dwek; Frances M Platt
Journal:  Ann Neurol       Date:  2004-11       Impact factor: 10.422

Review 4.  Multidrug permeases and subcellular cholesterol transport.

Authors:  Y A Ioannou
Journal:  Nat Rev Mol Cell Biol       Date:  2001-09       Impact factor: 94.444

5.  Occurrence of Parkinson's syndrome in type I Gaucher disease.

Authors:  O Neudorfer; N Giladi; D Elstein; A Abrahamov; T Turezkite; E Aghai; A Reches; B Bembi; A Zimran
Journal:  QJM       Date:  1996-09

6.  Adult GM1 gangliosidosis: immunohistochemical and ultrastructural findings in an autopsy case.

Authors:  K Yoshida; S Ikeda; K Kawaguchi; N Yanagisawa
Journal:  Neurology       Date:  1994-12       Impact factor: 9.910

Review 7.  Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.

Authors:  Robin H Lachmann
Journal:  Drugs Today (Barc)       Date:  2006-01       Impact factor: 2.245

8.  Late-onset Tay-Sachs disease: the spectrum of peripheral neuropathy in 30 affected patients.

Authors:  Barbara E Shapiro; Eric L Logigian; Edwin H Kolodny; Gregory M Pastores
Journal:  Muscle Nerve       Date:  2008-08       Impact factor: 3.217

9.  Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

Authors:  N Tayebi; J Walker; B Stubblefield; E Orvisky; M E LaMarca; K Wong; H Rosenbaum; R Schiffmann; B Bembi; E Sidransky
Journal:  Mol Genet Metab       Date:  2003-06       Impact factor: 4.797

10.  Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.

Authors:  Cristin D Davidson; Nafeeza F Ali; Matthew C Micsenyi; Gloria Stephney; Sophie Renault; Kostantin Dobrenis; Daniel S Ory; Marie T Vanier; Steven U Walkley
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

View more
  99 in total

1.  Port-to-port delivery: Mobilization of toxic sphingolipids via extracellular vesicles.

Authors:  Giuseppe Scesa; Ana Lis Moyano; Ernesto R Bongarzone; Maria I Givogri
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

2.  Fluid levity of the cell: Role of membrane lipid architecture in genetic sphingolipidoses.

Authors:  Ludovic D'Auria; Ernesto R Bongarzone
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

3.  Sphingosine and Sphingosine Kinase 1 Involvement in Endocytic Membrane Trafficking.

Authors:  Santiago Lima; Sheldon Milstien; Sarah Spiegel
Journal:  J Biol Chem       Date:  2017-01-03       Impact factor: 5.157

4.  Yeast and human P4-ATPases transport glycosphingolipids using conserved structural motifs.

Authors:  Bartholomew P Roland; Tomoki Naito; Jordan T Best; Cayetana Arnaiz-Yépez; Hiroyuki Takatsu; Roger J Yu; Hye-Won Shin; Todd R Graham
Journal:  J Biol Chem       Date:  2018-12-10       Impact factor: 5.157

Review 5.  Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.

Authors:  Klaudia Brix; Joseph McInnes; Alaa Al-Hashimi; Maren Rehders; Tripti Tamhane; Mads H Haugen
Journal:  Protoplasma       Date:  2014-11-16       Impact factor: 3.356

Review 6.  Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.

Authors:  Richard L Proia; Timothy Hla
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

7.  Targeted Analysis of Lysosomal Directed Proteins and Their Sites of Mannose-6-phosphate Modification.

Authors:  Tomislav Čaval; Jing Zhu; Weihua Tian; Sanne Remmelzwaal; Zhang Yang; Henrik Clausen; Albert J R Heck
Journal:  Mol Cell Proteomics       Date:  2018-09-20       Impact factor: 5.911

Review 8.  Glycosphingolipids and cell death: one aim, many ways.

Authors:  Carmen Garcia-Ruiz; Albert Morales; José C Fernández-Checa
Journal:  Apoptosis       Date:  2015-05       Impact factor: 4.677

Review 9.  Genetic convergence of Parkinson's disease and lysosomal storage disorders.

Authors:  Hao Deng; Xiaofei Xiu; Joseph Jankovic
Journal:  Mol Neurobiol       Date:  2014-08-07       Impact factor: 5.590

Review 10.  Combination Therapies for Lysosomal Storage Diseases: A Complex Answer to a Simple Problem.

Authors:  Shannon L Macauley
Journal:  Pediatr Endocrinol Rev       Date:  2016-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.